Abdominal distention is produced by abnormal somatic postural tone. We developed an original biofeedback technique based on electromyography-guided control of abdominothoracic muscular activity. We performed a randomized, placebo-controlled study to demonstrate the superiority of biofeedback to placebo for the treatment of abdominal distention.
A bdominal distention is one of the most frequent causes of consultation in gastroenterology clinics, and in most patients, no detectable cause can be found. Most of these patients fulfill the diagnostic criteria belonging to functional gut disorders, particularly irritable bowel syndrome or functional dyspepsia. 1, 2 Abdominal distention usually occurs in discrete episodes after meals and resolves after overnight fast. [3] [4] [5] The first question that needs to be addressed by the attending physician is whether the patient complaints are objective. A series of studies from our laboratory and other groups have shown that the subjective sensation corresponds with visible abdominal distention and an increase in girth. 4, [6] [7] [8] Combining abdominal computed tomography imaging morphologic studies with abdominothoracic wall electromyography (EMG) functional studies, we further showed that in patients with functional gut disorders, abdominal distention does not involve a substantial increase in intra-abdominal volume; however, it instead involves dystony of the abdominothoracic walls and redistribution of content. 4 Indeed, episodes of abdominal distention were associated with thoracic insufflation and diaphragmatic tone increase driving contents downward, coupled with reduced tone and ventral protrusion of the anterior wall. Based on these data, we developed an original biofeedback technique to correct abdominothoracic muscular dystony using EMG guidance, and in a pilot study, demonstrated the efficacy of this treatment. 4 The aim of the current study was to show the effect of biofeedback on abdominal distention in a randomized controlled trial.
Materials and Methods

Participants
Consecutive naive patients complaining of visible abdominal distention triggered by meal ingestion were prospectively included in the study. Relevant organic or psychiatric diseases were ruled-out by a clinical work-up: upper (n ¼ 27) and lower endoscopy (n ¼ 28), determination of celiac antibodies (n ¼ 25), and psychiatric evaluation (n ¼ 3) were performed if clinically indicated; per protocol, all participants underwent abdominal computed tomography imaging, which confirmed the lack of relevant abnormalities. Notably, only patients who reported variations of abdominal distention (ie, episodes of visible distention, related to meal ingestion in contrast to basal periods with mild or no distention) were included in the study. Each patient identified the most reproducible offending meal. Patients had not participated in any previous study or feedback treatment protocol.
The study protocol was approved by the institutional review board of the University Hospital Vall d'Hebron, and patients provided their written informed consent to participate in the study.
Experimental Design
This study was a randomized, placebo-controlled trial performed between January 2013 and January 2016 in a tertiary care referral center. The study protocol was registered with the ClincialTrials.gov number NCT01205100. All coauthors had access to the study data and reviewed and approved the final manuscript.
After inclusion in the study, patients were randomly allocated into the biofeedback or placebo group. Patients first underwent a pretreatment evaluation as described next. Patients were instructed to visit the laboratory under 2 different conditions: during fasting when they felt minimal or no abdominal distention (pretreatment basal session), and during an episode of visible distention after eating the recognized offending meal (pretreatment distention session). The study treatment, either placebo or biofeedback, was then delivered in 3 sessions over a 10-day period. Patients were instructed not to modify their habitual diet during the study and to eat the same offending meals before each treatment session than in the pretreatment distention session.
Before and immediately after treatment, patients in both groups underwent a 10-day clinical evaluation using daily questionnaires. The primary outcome of the study was visible abdominal distention measured daily by a graphic rating scale over the 10-day clinical evaluation period, before and immediately after intervention (see Clinical Outcome); participants were instructed to rate the degree of visible abdominal distention. Secondary outcomes included changes in abdominothoracic muscular activity, thoracic perimeter, and girth by the end of the third intervention session in reference to the pretreatment distention session (see Evaluation of Abdominothoracic Muscular Walls).
After completing all 3 treatment sessions, patients allocated to placebo were then offered the biofeedback treatment. All patients who underwent the biofeedback treatment, both the patients originally allocated by randomization and those patients who subsequently underwent biofeedback after initial placebo treatment, were followed up by 10-day clinical evaluations (see Clinical Outcome) at 1, 3, and 6 months. No medications related to intestinal function or psychotropic drugs were allowed during the study.
Randomization and Masking
Participants were randomized by a computergenerated randomization list. Participants were informed that the objective of the study was to test the response to a treatment for abdominal distention by means of questionnaires and recording the activity of the abdominothoracic walls in the laboratory. After randomization, each patient received an explanation about the treatment he or she was going to receive, without being aware of whether they were assigned to test or the control group, and all underwent the same instrumental interventions.
Evaluation of Abdominothoracic Muscular Walls
The measurements discussed next were performed during each pretreatment evaluation session (basal and distention) and at the beginning and the end of each intervention session (biofeedback or control).
Electromyography of the abdominothoracic walls. The activity of the intercostal, anterior abdominal wall (external oblique, upper rectus, lower rectus, and internal oblique muscles), and diaphragm was recorded by EMG in a quiet isolated room where participants sat erect on an ergonomic chair. This technique has been previously validated and described in detail. 4, 9, 10 Activity of the external oblique, upper rectus, lower rectus, and internal oblique muscles at the right side of the abdomen was recorded via bipolar leads 4, 11 ; intercostal muscle activity was recorded via a monopolar electrode at the second intercostal space on the right midclavicular line and a ground electrode over the center of the sternum. 12, 13 The appropriate location of abdominothoracic electrodes was verified by recording the EMG responses to a Valsalva maneuver (abdominal wall contraction) and deep inspiration (intercostal muscle contraction).
Diaphragmatic EMG activity was measured via intraesophageal electrodes mounted over a probe. The probe consisted of a polyvinyl tube (5 mm external diameter, 3 mm internal diameter) with 6 ring electrodes, 5 mm wide at 15-mm intervals. Bipolar EMG activity was recorded from contiguous electrodes. The electrodes were composed of a silver mixture (Conductive Pen, Chemotronics, Leeds, United Kingdom) and were connected to external plugs by insulated copper wires (200 mm in diameter) running through the lumen of the tube. After nasal intubation, the electrodes were positioned across the diaphragmatic hiatus under fluoroscopic control. The exact location of the diaphragmatic hiatus was determined at the beginning of each session by recording the responses to a Valsalva maneuver: the 2 bipolar leads recording the strongest signal were selected, and diaphragmatic activity was measured using the average of the 2 leads; this technique has been validated in detail. 14 To suppress electrocardiographic interferences, 0.2-second intervals were removed from the diaphragmatic EMG signal around every QRS peak using a specifically developed digital filter.
Sensation of abdominal distention. The patient's subjective abdominal distention sensation was measured on a graphic rating scale graded from 0 (no distention) to 6 (extremely severe distention). 4 Abdominal and thoracic perimeter measurement. This method has been previously described and validated in detail. 10, [15] [16] [17] [18] Briefly, a nonstretch belt (48-mm wide) with a metric tape measure fixed over it was placed over the umbilicus to measure girth; another belt was placed below the mammary glands to measure thoracic perimeter. The overlapping ends of each belt were adjusted carefully by 2 elastic bands to maintain the belt constantly adapted to the abdominal wall. Measurements were taken with the subjects breathing quietly as the average of inspiratory and expiratory determinations over 3 consecutive respiratory cycles without manipulation of the belt-tape assembly by the investigator. In the first pretreatment recording session, the location of the belts was marked on the skin for subsequent measurements. During each intervention session (biofeedback or control), the belts were kept in place for repeat measurements (at the beginning and at the end of the session).
Intervention
The study treatment, either biofeedback or placebo, was delivered in 3 sessions, lasting approximately 30 minutes each, over a 10-day period and with the same instrumental interventions. Patients were instructed to visit the hospital after eating the recognized offending meal and abdominothoracic EMG activity was served.
Biofeedback. Patients allocated to biofeedback received EMG-guided training during the 3 treatment sessions. 4 Patients were trained to control the activity of the abdominothoracic muscles under visual control of EMG recordings displayed on a monitor. Specifically, they were instructed to reduce the activity of intercostal muscles and the diaphragm, while increasing the activity of the anterior abdominal muscles. After each biofeedback session, patients were instructed to perform the same exercises daily at home for 5 minutes before and after breakfast, lunch, and dinner. At the end of the treatment period, patients were encouraged to continue practicing these same exercises over time.
Placebo. In the placebo group, in each of the 3 sessions, patients were given a capsule of simethicone (120 mg) to ingest, while abdominothoracic wall EMG activity was recorded in the same way as in the biofeedback group. During the 10-day treatment period, the patients were instructed to take a capsule of simethicone (120 mg) before breakfast, lunch, and dinner.
Clinical Outcome
The clinical outcome was measured by asking patients to fill out the clinical questionnaires for 10 consecutive days before treatment and at different time points after treatment (immediately after and at 1, 3, and 6 months). The questionnaire included 2 graphic rating scales graded from 0 (none) to 6 (very severe sensation), 1 scale to score visible abdominal distention and the other to score associated abdominal symptoms with the instruction to specify the type of sensation perceived (1 or more of the following list: fullness, puncture/ stinging sensation, pyrosis, early satiation, nausea, discomfort/pain, and other); participants were instructed to fill-out the scales after lunch and dinner. In previous studies we showed that the distention scale consistently reflects changes in girth measured by tape measure or by computed tomography scans in the same individuals under different conditions. 4, 19, 20 
Data Analysis
In each subject, distention scores and associated symptom scores in the questionnaires were averaged every day and over the 10-day evaluation periods. In the pretreatment evaluation sessions (basal and distention), and at the beginning and at the end of each treatment session (biofeedback or placebo), EMG activity at each site was measured as the root mean square voltage averaged over 1-minute periods. 15, 21 In each subject, the treatment effect was measured as the difference between the value in the pretreatment distention session and the value at the end of the third treatment session, and the data in the biofeedback versus placebo groups were compared.
Statistical Analysis
The sample size calculation was based on a previous pilot study. 4 Assuming a reduction of sensation of abdominal distention after treatment of 70% for biofeedback and 30% for placebo, 24 subjects per group were necessary to discriminate differences in the reduction of the abdominal distention score (primary outcome) between the 2 groups with a power of 80% and a significance level of 5%.
In each group, means (or grand means) and standard error of the measured variables were calculated. The Kolmogorov-Smirnov test was used to check the normality of data distribution. Parametric normally distributed data were compared by Student t test for paired or unpaired data; otherwise, the Wilcoxon signed rank test was used for paired data, and the MannWhitney U test was used for unpaired data. The association of parameters was analyzed using linear regression analysis.
Results
Pretreatment Evaluation
Demographics. Forty-eight patients were selected and included in the study (Figure 1 , Table 1 ). All patients (n ¼ 48) had a functional disorder diagnosis based on the Rome III criteria (Table 1) .
1,2 Symptom duration was similar in the 2 groups.
Clinical data. During the 10-day pretreatment evaluation period, the patients reported subjective sensation of abdominal distention (4.6 AE 0.1 score) ( Figure 2 ). All patients also reported associated abdominal symptoms; the predominant symptom was abdominal fullness in 60% AE 3% of the patients, early satiation in 36% AE 2%, and discomfort/pain in 3% AE 2%. The severity of these associated symptoms was similar in both groups (Table 1) .
Abdominothoracic muscular activity during abdominal distention versus basal conditions. During the pretreatment evaluation all patients exhibited consistent differences between basal and distending sessions. During the distention session (after ingestion of the offending meal) all patients reported higher sensation of abdominal distention (4.9 AE 0.1 score vs 1.9 AE 0.1 score in the basal session; P < .001), and exhibited larger abdominal girth measured by tape measure (23 mm AE 2 mm larger than in the basal session; P < .001) and larger thoracic perimeter (15 mm AE 1 mm larger than in the basal session; P < .001). In all patients abdominal distention was associated with reduced EMG activity of the anterior wall muscles (consistent with girth increment and protrusion of the anterior wall), increased EMG activity of the diaphragm (consistent with a diaphragmatic descent), and increased EMG activity of intercostal muscles (consistent with costal wall expansion) ( Table 2 ). No differences in the pretreatment evaluation were detected between study groups (Table 2) .
Reponses During the Treatment Sessions
Two patients allocated to the placebo withdrew (because of work constraints they could not attend the treatment sessions), and the remaining patients completed the treatment and were included in the outcomes' analysis ( Figure 1) . Figure 1 . Flow chart. At study entry, 48 patients were randomized; 2 patients allocated to placebo withdrew and 2 patients in the biofeedback group were lost to follow-up (did not complete the questionnaires) and were not included in the primary outcome analysis. Patients who did not improve with placebo (n ¼ 19) received biofeedback treatment afterward. All patients who received biofeedback (n ¼ 41 valid for analysis) were followed up at 1, 3, and 6 months after treatment. In the biofeedback group all patients learned to correct their postural tone. Indeed, biofeedback significantly modified the activity of the abdominothoracic muscles (n ¼ 24), whereas the placebo (n ¼ 22) had no effect (Figure 2) . Compared with the pretreatment distention session, at the end of the third biofeedback session, EMG activity of the intercostals and diaphragm significantly decreased, whereas abdominal muscle activity significantly increased. These changes in muscular activity were associated with a decrease in girth and thoracic perimeter, and improvement in the subjective sensation of abdominal distention (Figure 3 ). These changes in the biofeedback group (all but thoracic perimeter) were significantly larger than those in the placebo group (Figures 2 and 3) .
Clinical Outcome Immediately After Treatment Period
After undergoing the 3 treatment sessions, patients completed the 10-day clinical questionnaire. Two patients in the biofeedback group did not complete the questionnaires (were lost to follow-up) and were not valid for the primary outcome analysis ( Figure 1) ; to note, their responses on postural tone, girth, and distention scores during the treatment sessions were similar to the rest. After the treatment sessions, the sensation of abdominal distention had decreased by 56% AE 4% in the biofeedback group (n ¼ 22) but only by 13% AE 8% in the placebo group (n ¼ 22; P < .001) (Figure 4 ). Associated abdominal symptoms were reduced by 57% AE 9% in the biofeedback group and by 23% AE 4% in the placebo group (P ¼ .023). The effect of treatment did not depend on the type of associated symptoms, and no side effects were reported.
Follow-up After Biofeedback Treatment
The 19 patients who did not improve with placebo treatment subsequently received biofeedback treatment (Figure 3) . The effect of biofeedback in these patients was similar to the benefit experienced by the patients originally allocated to the biofeedback group both during the treatment sessions (the EMG activity change, girth decrease, and improved sensation of abdominal distention) and after treatment (Figure 3) . The response to biofeedback treatment was similar in the 2 groups; therefore, the 6-month follow-up data for all the patients who underwent biofeedback treatment were pooled together (n ¼ 41).
The score of abdominal distention decreased to 1.7 AE 0.1 immediately after biofeedback, 0.9 AE 0.1 by 1 month, 0.4 AE 0.1 by 3 months, and 0.3 AE 0.1 by 6 months (P < .001 vs 4.6 AE 0.1 were before treatment for all; P < .001 at 6 months vs immediately after treatment).
The associated abdominal symptoms reported by patients treated with biofeedback also continued to gradually improve during follow-up (symptoms scores progressively dropped from 2.8 AE 0.2 pretreatment to Figure 2 . Effects during treatment on abdominothoracic muscle activity. Changes at the end of the third treatment session from pretreatment distention session. Biofeedback significantly modified the activity of abdominothoracic muscles (n ¼ 24), whereas placebo (n ¼ 22) had no effect. Several patients did not tolerate esophageal intubation in all sessions, hence diaphragmatic EMG recordings during both the pretreatment distention session and the third treatment session for paired analysis were only partly available (n ¼ 11 in the biofeedback group; n ¼ 11 in the placebo group). 1.0 AE 0.1 immediately after biofeedback, 0.5 AE 0.1 by 1 month, 0.3 AE 0.1 by 3 months, and 0.2 AE 0.1 by 6 months after treatment; P < .001 vs pretreatment for all).
Discussion
This randomized placebo-controlled trial indicates that a behavioral intervention targeting postural tone of abdominothoracic walls is effective for the treatment of abdominal distention in patients without a primary cause.
We included patients with transient episodes of visible abdominal distention, and they were evaluated twice to determine the differences in postural tone during an episode of abdominal distention compared with basal conditions. Muscular tone was evaluated by EMG, and as in previous studies, 4, 10 abdominal distention was associated with an increase in girth, reduced tone of the anterior abdominal wall, increased tone of the diaphragm and the intercostal muscles, and increase in thoracic perimeter. Separate morphologic studies provide concordant information showing hyperinsufflation of the chest, caused by elevation of the costal wall and diaphragmatic descent (concordant with increased tone of the intercostal and the diaphragm, respectively), and anterior wall protrusion without major increment in gaseous or nongaseous abdominal content. 4, 7 To note, the current and previous series of studies 4 ,7 include a pool well over 100 patients.
Under normal conditions, the walls of the abdomen actively adapt its content by a continuous modulation of the muscle postural tone in the anterior wall, the diaphragm, and the chest, a phenomenon termed abdominal accommodation. 9, 14 An increase in abdominal content, such as by meal ingestion, induces a contraction of the anterior wall coupled with a relaxation and upward shift of the diaphragm to accommodate the ingested volume without major changes in girth; the costal walls also move upward to compensate for the diaphragmatic ascent. Abdominal distention is caused by a faulty abdominal accommodation, and the fact that conductual therapy corrected abdominal distention suggests that the underlying abnormal postural tone is a behavioral somatic response. However, why these patients acquired this abnormal behavior remains unknown, and which factors trigger the postural response also remains unknown. Studies using prolonged ambulatory recording Effects during treatment on abdominal distention (subjective sensation and girth). Changes at the end of the third treatment session from pretreatment distention session. Biofeedback (n ¼ 24) reduced the sensation of abdominal distention and girth, whereas placebo (n ¼ 22) had no effect.
of the girth showed that abdominal distention in patients with functional gut disorders (ie, without a detectable cause) exhibits fluctuations along the day with peaks following meals 8 ; anxiety and stress are also potential triggers or facilitating factors. A previous study showed that in patients complaining of postprandial distention, meal ingestion induced a paradoxical contraction of the diaphragm, anterior wall relaxation, and a significant girth increment. 10 Perception of digestive symptoms, such as postprandial fullness, in patients with functional dyspepsia may trigger the abnormal somatic response; however, some patients, specifically those labeled with functional abdominal distention, do not report associated symptoms. 1 Moreover, biofeedback treatment in our study improved associated symptoms, and this intriguing observation suggests that, rather than a triggering factor, they are secondary to distention.
Using the biofeedback technique, patients effectively learned to control abdominothoracic muscular activity, and correction of postural tone was associated with a reduction in girth back to baseline levels. The effect observed during the treatment sessions persisted afterward, and the sensation of distention during the 10-day evaluation period after biofeedback was lower than before. To note, all patients learned to correct their postural tone during the treatment sessions and all reported a subsequent improvement in distention. Furthermore, the change was significantly greater than with placebo treatment, which was the primary outcome of the study. Moreover, after placebo failure in the control group, subsequent biofeedback produced the same effect as in patients originally allocated to the biofeedback treatment. An ancillary, uncontrolled observation of the study was the progressive improvement of abdominal distention during the 6-month follow-up, which could be related, at least in part, to the continuous exercises the patients were instructed to practice. In contrast to distention, placebo had no effect on abdominal distention but improved other associated abdominal symptoms initially and further in the followup period.
By a series of studies, we first showed that abdominal distention is a real phenomenon that is not related to an increase in intra-abdominal content, but rather to an abnormal postural tone. We then developed a mechanistic treatment targeting the activity of the abdominothoracic muscles and in a pilot, not formally controlled, proof-of-concept study we showed the potential efficacy of this treatment. We have now demonstrated the superiority of this treatment to placebo using efficacy, randomized trial. Biofeedback in this trial was applied using a complex technique that provided effective guidance to patients and allowed close control of the mechanistic effects of the intervention on postural tone. Having proved the efficacy of this treatment, the next steps are to develop and then to properly validate a simpler technique for widespread application.
